Hepatitis C infection associated with renal disease and chronic renal failure

Fred F. Poordad, Fabrizio Fabrizi, Paul Martin

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Screening of blood products and attention to stricter infection control measures in hemodialysis units have reduced the incidence of hepatitis C virus (HCV) infection among dialysis patients. HCV can be transmitted via transplanted organs. Renal transplantation may accelerate the course of liver disease, which has an impact on patient and graft survival. Interferon (IFN) alfa monotherapy has produced promising results during treatment but disappointing long-term results in patients with HCV-associated glomerulonephritis. Dialysis patients with HCV infection respond well to IFN-based therapy, and there appears to be clinical benefit in clearing HCV in renal transplantation candidates. Larger prospective trials are required to fully determine the role of IFN in these patient groups, including the potential use of IFN plus ribavirin and pegylated IFNs. IFN therapy in renal transplantation patients is not recommended because of potential graft rejection.

Original languageEnglish
Pages (from-to)69-77
Number of pages9
JournalSeminars in Liver Disease
Volume24
Issue numberSUPPL. 2
DOIs
StatePublished - Aug 1 2004
Externally publishedYes

Fingerprint

Hepatitis C
Chronic Kidney Failure
Hepacivirus
Kidney
Interferons
Infection
Kidney Transplantation
Virus Diseases
Dialysis
Ribavirin
Graft Rejection
Graft Survival
Infection Control
Glomerulonephritis
Interferon-alpha
Renal Dialysis
Liver Diseases
Therapeutics
Incidence

Keywords

  • Chronic renal failure
  • HCV
  • Interferon
  • Renal disease
  • Renal transplantation

ASJC Scopus subject areas

  • Hepatology

Cite this

Hepatitis C infection associated with renal disease and chronic renal failure. / Poordad, Fred F.; Fabrizi, Fabrizio; Martin, Paul.

In: Seminars in Liver Disease, Vol. 24, No. SUPPL. 2, 01.08.2004, p. 69-77.

Research output: Contribution to journalArticle

Poordad, Fred F. ; Fabrizi, Fabrizio ; Martin, Paul. / Hepatitis C infection associated with renal disease and chronic renal failure. In: Seminars in Liver Disease. 2004 ; Vol. 24, No. SUPPL. 2. pp. 69-77.
@article{7825c6b5629a41a5ba828ec080639ee8,
title = "Hepatitis C infection associated with renal disease and chronic renal failure",
abstract = "Screening of blood products and attention to stricter infection control measures in hemodialysis units have reduced the incidence of hepatitis C virus (HCV) infection among dialysis patients. HCV can be transmitted via transplanted organs. Renal transplantation may accelerate the course of liver disease, which has an impact on patient and graft survival. Interferon (IFN) alfa monotherapy has produced promising results during treatment but disappointing long-term results in patients with HCV-associated glomerulonephritis. Dialysis patients with HCV infection respond well to IFN-based therapy, and there appears to be clinical benefit in clearing HCV in renal transplantation candidates. Larger prospective trials are required to fully determine the role of IFN in these patient groups, including the potential use of IFN plus ribavirin and pegylated IFNs. IFN therapy in renal transplantation patients is not recommended because of potential graft rejection.",
keywords = "Chronic renal failure, HCV, Interferon, Renal disease, Renal transplantation",
author = "Poordad, {Fred F.} and Fabrizio Fabrizi and Paul Martin",
year = "2004",
month = "8",
day = "1",
doi = "10.1055/s-2004-832931",
language = "English",
volume = "24",
pages = "69--77",
journal = "Seminars in Liver Disease",
issn = "0272-8087",
publisher = "Thieme Medical Publishers",
number = "SUPPL. 2",

}

TY - JOUR

T1 - Hepatitis C infection associated with renal disease and chronic renal failure

AU - Poordad, Fred F.

AU - Fabrizi, Fabrizio

AU - Martin, Paul

PY - 2004/8/1

Y1 - 2004/8/1

N2 - Screening of blood products and attention to stricter infection control measures in hemodialysis units have reduced the incidence of hepatitis C virus (HCV) infection among dialysis patients. HCV can be transmitted via transplanted organs. Renal transplantation may accelerate the course of liver disease, which has an impact on patient and graft survival. Interferon (IFN) alfa monotherapy has produced promising results during treatment but disappointing long-term results in patients with HCV-associated glomerulonephritis. Dialysis patients with HCV infection respond well to IFN-based therapy, and there appears to be clinical benefit in clearing HCV in renal transplantation candidates. Larger prospective trials are required to fully determine the role of IFN in these patient groups, including the potential use of IFN plus ribavirin and pegylated IFNs. IFN therapy in renal transplantation patients is not recommended because of potential graft rejection.

AB - Screening of blood products and attention to stricter infection control measures in hemodialysis units have reduced the incidence of hepatitis C virus (HCV) infection among dialysis patients. HCV can be transmitted via transplanted organs. Renal transplantation may accelerate the course of liver disease, which has an impact on patient and graft survival. Interferon (IFN) alfa monotherapy has produced promising results during treatment but disappointing long-term results in patients with HCV-associated glomerulonephritis. Dialysis patients with HCV infection respond well to IFN-based therapy, and there appears to be clinical benefit in clearing HCV in renal transplantation candidates. Larger prospective trials are required to fully determine the role of IFN in these patient groups, including the potential use of IFN plus ribavirin and pegylated IFNs. IFN therapy in renal transplantation patients is not recommended because of potential graft rejection.

KW - Chronic renal failure

KW - HCV

KW - Interferon

KW - Renal disease

KW - Renal transplantation

UR - http://www.scopus.com/inward/record.url?scp=4444232172&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4444232172&partnerID=8YFLogxK

U2 - 10.1055/s-2004-832931

DO - 10.1055/s-2004-832931

M3 - Article

C2 - 15346249

AN - SCOPUS:4444232172

VL - 24

SP - 69

EP - 77

JO - Seminars in Liver Disease

JF - Seminars in Liver Disease

SN - 0272-8087

IS - SUPPL. 2

ER -